Abstract:EGFR T790M mutation accounts for more than 50% of acquired resistance to TKI. In pre-clinical, EGFR-TKI resistant cells with T790M exhibited enhanced sensitivity to radiation, suggesting the potential of radiotherapy in reduction and delay of T790M-mediated EGFR TKI resistance. Under different radiotherapy dose and times, we use droplet digital PCR to observe the emerging time of T790M and its proportion during chronic exposure to gefitinib in TKI-sensitivity cell lines, and to evaluate the anti-tumor effect of early radiation combined with gefitinib in xenograft model with different proportion of T790M. Furthermore, we performed miRNA microarray to screen miRNAs differentially expressed in the paired NSCLC gefitinib-sensitivity cell lines and gefitinib resistant cell lines and find potential molecular markers of T790M mutation. Our data showed radiation combined with gefitinib delayed the occurrence of EGFR T790M mutation compared to gefitinib alone in T790M wild type (TKI-sensitive) cell line and it also reduced the T790M mutation abundance in de novo T790M mutation (TKI-resistant) cell line. The phenomena was also confirm in mice xenograft model. In addition, our results showed TKI-resistant (induced T790M mutation) cells had higher radiosensitivity than TKI-sensitive cells. miRNA array showed miR-1275 was the one of the most significantly elevated miRNAs in TKI-resistant cells. Knockdown of miRNA-1275 significantly decreased the radiosensitivity of TKI-resistant cells. Western blot showed knockdown of miR-1275 affected proteins relating to cell proliferation and apoptosis. Bioinformatics showed SPOCK1 might be one of the targets of miRNA-1275. Our results contribute to understand molecular mechanisms of T790M-mediated EGFR-TKI resistance, but also provide a new therapeutic strategy for patients in advanced NSCLC to aid expansion of the effectiveness of TKI treatment through radiotherapy.

Nuclear EGFR:a Potential Target for Radiosensitizer

Role of nuclear epidermal growth factor receptor in tumorigenesis and resistant to treatment

Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function

Nuclear epidermal growth factor receptor as a therapeutic target

EGFR and Radiosensitization of Tumor Cells

Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies

Targeting Nrf2/PHKG2 Axis to Enhance Radiosensitivity in NSCLC.

The Inhibition Of Egfr Nuclear Translocation Attenuates Radioresistance Through Decreasing The Expression Of P-Dna-Pk In Cervical Cancer Cells

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

EGFR inhibitors and radiosensitivity of tumor cells

P2.05-005 Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance: Topic: Biology

Inhibition of EGFR Nuclear Translocation Attenuate Radioresistance Through Decreased P-Dna-pk Expression in Cervical Cancer Cells.

Role of Epidermal Growth Factor Receptor in Tumor Radiotherapy

Progression in the mechanisms of EGFR inhibitors combined with radiotherapy

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].

Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

Application of nanomedicine in radiotherapy sensitization

Nuclear EGFR-PKM2 Axis Induces Cancer Stem Cell-Like Characteristics in Irradiation-Resistant Cells.

The Relativity of EGFR and Autophagy in the Regulating Radiation Sensitivity of Brain Glioma Cells

Combining radiotherapy with EGFR inhibitor for NSCLC:principle and present status